Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 431Carcinoma, Non-Small-Cell Lung 372Neoplasms 324Prostatic Neoplasms 244Leukemia, Myeloid, Acute 230Multiple Myeloma 229Neoplasm Metastasis 215Melanoma 200Lung Neoplasms 178Leukemia 172Lymphoma 170Colorectal Neoplasms 157Pancreatic Neoplasms 151Lymphoma, Non-Hodgkin 150Recurrence 149Ovarian Neoplasms 143Leukemia, Lymphocytic, Chronic, B-Cell 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 131Myelodysplastic Syndromes 121Carcinoma, Renal Cell 120Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Follicular 108Brain Neoplasms 99Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 96Glioblastoma 92Urinary Bladder Neoplasms 88Carcinoma, Hepatocellular 80Hodgkin Disease 73Colonic Neoplasms 73

Interventions

selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Has results × Castration Levels of Testosterone × Clear all
NCT02215161 2018-06-26

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
14 enrolled 12 charts
Genitourinary

Castration Levels of Testosterone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡